Business Monitor International


Czech Republic Pharmaceuticals & Healthcare Report

Published 08 October 2014

  • 101 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Czech Republic Pharmaceuticals & Healthcare Report

BMI View:   The pharmaceutical supply chain within the Czech Republic has undergone a period of flux over the last decade. The pharmaceutical market itself, originally dominated by domestic and regional generic companies, has been won over by larger multinationals with competitive pressures expected to continue to favour those with scale. While we expect the Czech market to stabilise in 2014, we note that depreciatory pressure on the Czech koruna could see incomes decline for multinationals that operate within the Czech Republic. In addition, policies that regulate drug prices even further and reduce the cost of medicines to the state healthcare system and private insurers will weigh heavily on the growth prospects of the Czech pharmaceutical market, even as the Czech economy rebounds in 2015. Despite these concerns, BMI maintains a more optimistic long-term view. We believe that the need for innovative medicines will drive growth well above the rates of expansion achieved in Western Europe over our 10-year forecast period. In the longer term, the Czech Republic's disease and drug consumption profile illustrates a considerable gap between it and Western Europe, suggesting that the population's demand for high-value innovative medicines will continue until convergence. 

Headline Expenditure Projections

  • Pharmaceuticals: CZK76.93bn (USD3.66bn) in 2013 to CZK74.43bn (USD3.41bn) in 2014; -3.2% in local currency terms and -6.7% in US dollar terms. Forecasts significantly lower compared to previous quarter.

  • Healthcare: CZK290.94bn (USD13.83bn) in 2013 to CZK305.59bn (USD14.02bn) in 2014; +5.0% in local currency terms and 1.3% in US dollar terms. Forecasts changed due to historical revision to 2012 figures.

Risk/Reward Rating: Despite leading our regional RRR table with a score of 63.2 out of 100 and therefore ranked as the most attractive market in the Central and Eastern European region followed by Poland (61.5) and Greece (57.8) in Q414, drugmakers will...

Table of Contents

BMI Industry View
7
SWOT
11
Political
13
Economic
14
Business Environment
15
Industry Forecast
16
Pharmaceutical Market Forecast
16
Table: Pharmaceutical Sales, Historical Data And Forecasts (Czech Republic 2010-2018)
18
Healthcare Market Forecast
20
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Czech Republic 2010-2018)
23
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Czech Republic 2010-2018)
23
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Czech Republic 2010-2018)
24
Prescription Drug Market Forecast
25
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Czech Republic 2010-2018)
26
Patented Drug Market Forecast
27
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Czech Republic 2010-2018)
28
Generic Drug Market Forecast
29
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Czech Republic 2010-2018)
29
OTC Medicine Market Forecast
30
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Czech Republic 2010-2018)
32
Pharmaceutical Trade Forecast
33
Table: Pharmaceutical Trade Data And Forecasts (Czech Republic 2012-2018)
34
Table: Pharmaceutical Trade Data And Forecasts Local Currency (Czech Republic 2012-2018)
34
Other Healthcare Data
35
Key Risks To BMI's Forecast Scenario
36
Macroeconomic Forecasts
37
Economic Analysis
37
Table: Economic Activity (Czech Republic 2009-2018)
39
Industry Risk Reward Ratings
40
Central And Eastern Europe Risk/Reward Ratings
40
Czech Republic Risk/Reward Ratings
47
Rewards
47
Risks
47
Market Overview
48
Industry Trends And Developments
49
Epidemiology
49
Healthcare Sector
50
Healthcare Insurance
51
Healthcare Reforms
52
Hospital Sector
56
Research & Development
56
Clinical Trials
59
Regulatory Development
61
Regulatory Regime
61
Intellectual Property Environment
61
Prescribing Rules
62
Pharmaceutical Advertising
62
Pricing Regime
64
Reimbursement Regime
64
Recent Pricing And Reimbursement Developments
65
Changes To VAT
69
Table: European VAT Rates On Medicines (%)
70
Electronic Tenders
71
Competitive Landscape
72
Pharmaceutical Sector
72
Foreign Industry
73
Pharmaceutical Wholesale
74
Pharmaceutical Retail Sector
74
Table: Retail Pharmacy Market Overview, 2006-2012
74
Company Profile
77
Zentiva (Sanofi)
77
Walmark
81
AstraZeneca
85
Bristol-Myers Squibb
87
Sanofi
89
Novartis
92
GlaxoSmithKline
94
Pfizer
97
Demographic Forecast
99
Table: The Czech Republic's Population By Age Group, 1990-2020 ('000)
100
Table: The Czech Republic's Population By Age Group, 1990-2020 (% of total)
101
Table: The Czech Republic's Key Population Ratios, 1990-2020
102
Table: The Czech Republic's Rural And Urban Population, 1990-2020
102
Glossary
103
Methodology
105
Pharmaceutical Expenditure Forecast Model
105
Healthcare Expenditure Forecast Model
105
Notes On Methodology
106
Risk/Reward Ratings Methodology
107
Ratings Overview
108
Table: Pharmaceutical Risk/Reward Ratings Indicators
108
Indicator Weightings
109

The Czech Republic Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Czech Republic Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Czech pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Czech Republic to test other views - a key input for successful budgeting and strategic business planning in the Czech pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Czech pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Czech Republic.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc